My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

Supreme Petrochem standalone net profit rises 40.06% in the December 2016 quarter
Jan 25,2017

Net profit of Supreme Petrochem rose 40.06% to Rs 35.42 crore in the quarter ended December 2016 as against Rs 25.29 crore during the previous quarter ended December 2015. Sales rose 14.29% to Rs 686.34 crore in the quarter ended December 2016 as against Rs 600.50 crore during the previous quarter ended December 2015.

ParticularsQuarter Endedn++Dec. 2016Dec. 2015% Var. Sales686.34600.50 14 OPM %8.545.44 - PBDT58.6231.82 84 PBT53.0126.17 103 NP35.4225.29 40

Powered by Capital Market - Live News

Swaraj Engines standalone net profit rises 83.23% in the December 2016 quarter
Jan 25,2017

Net profit of Swaraj Engines rose 83.23% to Rs 15.30 crore in the quarter ended December 2016 as against Rs 8.35 crore during the previous quarter ended December 2015. Sales rose 46.58% to Rs 154.07 crore in the quarter ended December 2016 as against Rs 105.11 crore during the previous quarter ended December 2015.

ParticularsQuarter Endedn++Dec. 2016Dec. 2015% Var. Sales154.07105.11 47 OPM %14.9212.14 - PBDT27.3816.46 66 PBT23.4313.21 77 NP15.308.35 83

Powered by Capital Market - Live News

GMM Pfaudler standalone net profit rises 14.54% in the December 2016 quarter
Jan 25,2017

Net profit of GMM Pfaudler rose 14.54% to Rs 5.83 crore in the quarter ended December 2016 as against Rs 5.09 crore during the previous quarter ended December 2015. Sales rose 9.77% to Rs 65.84 crore in the quarter ended December 2016 as against Rs 59.98 crore during the previous quarter ended December 2015.

ParticularsQuarter Endedn++Dec. 2016Dec. 2015% Var. Sales65.8459.98 10 OPM %16.1315.16 - PBDT10.969.40 17 PBT9.057.80 16 NP5.835.09 15

Powered by Capital Market - Live News

Wendt India standalone net profit rises 11.73% in the December 2016 quarter
Jan 25,2017

Net profit of Wendt India rose 11.73% to Rs 2.19 crore in the quarter ended December 2016 as against Rs 1.96 crore during the previous quarter ended December 2015. Sales rose 14.32% to Rs 32.17 crore in the quarter ended December 2016 as against Rs 28.14 crore during the previous quarter ended December 2015.

ParticularsQuarter Endedn++Dec. 2016Dec. 2015% Var. Sales32.1728.14 14 OPM %17.1916.20 - PBDT5.714.90 17 PBT3.222.78 16 NP2.191.96 12

Powered by Capital Market - Live News

Saurashtra Cement reports standalone net loss of Rs 16.95 crore in the December 2016 quarter
Jan 25,2017

Net Loss of Saurashtra Cement reported to Rs 16.95 crore in the quarter ended December 2016 as against net loss of Rs 2.55 crore during the previous quarter ended December 2015. Sales declined 11.28% to Rs 111.20 crore in the quarter ended December 2016 as against Rs 125.34 crore during the previous quarter ended December 2015.

ParticularsQuarter Endedn++Dec. 2016Dec. 2015% Var. Sales111.20125.34 -11 OPM %-15.570.06 - PBDT-16.793.11 PL PBT-20.42-0.01 -204100 NP-16.95-2.55 -565

Powered by Capital Market - Live News

Quick Heal Technologies to announce Q3 and 9M results
Jan 25,2017

Quick Heal Technologies announced that a meeting of the Board of Directors of the Company will be held on 03 February 2017, inter alia, to consider and approve standalone unaudited financial results of the Company for the quarter and nine months ended on December 31, 2016.

Powered by Capital Market - Live News

Biocon moves higher after strong Q3 earnings
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 107.56 points or 0.39% at 27,483.14.

On the BSE, 89,000 shares were traded on the counter so far as against the average daily volumes of 75,023 shares in the past one quarter. The stock had hit a high of Rs 1,049 and a low of Rs 1,013 so far during the day.

The stock had hit a record high of Rs 1,052.05 on 12 January 2017 and a 52-week low of Rs 430.80 on 12 February 2016. The stock had outperformed the market over the past one month till 24 January 2017, advancing 7.37% compared with the Sensexs 5.13% rise. The scrip had also outperformed the market over the past one quarter, gaining 2.87% as against the Sensexs 2.85% fall.

The large-cap company has equity capital of Rs 100 crore. Face value per share is Rs 5.

Biocons consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) rose 57% to Rs 324 crore in Q3 December 2016 over Q3 December 2015.

Commenting on the companys quarterly performance, Biocons Chairperson and Managing Director, Kiran Mazumdar-Shaw said, the companys strong performance in Q3 December 2016 was led by robust growth of its biologics business with both insulins and biosimilar MAbs gaining traction in Japan and key emerging markets. The companys small molecules and research services businesses also reported strong growth this quarter, she said.

Separately, Biocon before market hours today, 25 January 2017 announced that the Ministry of Health (MoH), Malaysia, has awarded a three year contract, to its subsidiary, Biocon SDN. BHD., Malaysia, for supplying recombinant human insulin (rh-Insulin) formulations manufactured at its large scale biopharmaceutical facility in Johor, Malaysia. Biocons rh-Insulin is Malaysias first locally manufactured biosimilar biologic product approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia, for commercial sales in the country. This marks the commercialization milestone of Biocons first overseas facility in Malaysia.

Biocon SDN. BHD. has been awarded a MYR 300 million (about Rs 460 crore) contract to be serviced over a period of three years for supplying rh-Insulin cartridges and re-usable insulin pens under the Malaysian governments Off-Take Agreement (OTA) initiative, which seeks to encourage local manufacturing of new pharmaceutical products thus lowering the countrys reliance on imports and also enhancing the exports potential. The contract is extendable for additional two years subject to approval by the Government of Malaysia.

Biocon will distribute insulins and insulin delivery devices through CCM Pharmaceuticals, a leading local pharmaceutical player which has an extensive supply chain network to service primary healthcare clinics and hospitals across Malaysia.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

Siemens gains after winning order
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 103.95 points, or 0.38%, to 27,479.53.

On the BSE, so far 8,384 shares were traded in the counter, compared with average daily volumes of 19,295 shares in the past one quarter. The stock had hit a high of Rs 1,185 and a low of Rs 1,168.55 so far during the day.

The stock hit a 52-week high of Rs 1,355.40 on 25 July 2016. The stock hit a 52-week low of Rs 969 on 29 January 2016. The stock had outperformed the market over the past 30 days till 24 January 2017, rising 10.92% compared with the 6.08% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 2.65% as against Sensexs 1.66% decline.

The large-cap company has equity capital of Rs 71.22 crore. Face value per share is Rs 2.

Siemens announced that it has won an order worth approximately Rs 366 crore from Oil and Natural Gas Corporation (ONGC). The order includes supply of material for overhauling of 18 power turbines through zero hour overhaul and time continued overhaul.

Net profit of Siemens rose 1025.8% to Rs 2466.95 crore on 7.5% decline in net sales to Rs 2990.30 crore in Q4 September 2016 over Q4 September 2015.

Siemens focuses on the areas of electrification, automation and digitalization. As on 31 December 2016, Siemens AG held 74.16% stake in Siemens.

Powered by Capital Market - Live News

Tinplate Company of India postpones board meeting to consider Q3 results
Jan 25,2017

Tinplate Company of India announced that the Board Meeting scheduled to be held on 31 January 2017, will now be held on 02 February 2017, inter alia, to approve and take on record the Audited Financial Results of the Company for the quarter and nine months ended 31 December 2016.

Powered by Capital Market - Live News

Wockhardt slips after weak Q3 results
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 125.24 points, or 0.46%, to 27,500.82.

On the BSE, so far 72,000 shares were traded in the counter, compared with average daily volumes of 1.92 lakh shares in the past one quarter. The stock had hit a high of Rs 671.70 and a low of Rs 656.60 so far during the day.

The stock hit a 52-week high of Rs 1,296 on 29 January 2016. The stock hit a 52-week low of Rs 627 on 27 December 2016. The stock had outperformed the market over the past 30 days till 24 January 2017, rising 7.40% compared with the 6.08% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 20.92% as against Sensexs 1.66% decline.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardts total income dropped 10.34% to Rs 1000.81 crore in Q3 December 2016 over Q3 December 2015. Sales fell 7.44% to Rs 995 crore in Q3 December 2016 over Q3 December 2015.

Earnings before interest, tax, depreciation and amortization (EBITDA) fell 75.68% to Rs 18 crore in Q3 December 2016 over Q3 December 2015. EBITDA margin was reported at 1.8% in Q3 December 2016, lower than 6.9% in in Q3 December 2015.

The companys performance during the quarter was affected by subdued business in US market, demonetisation in India and continued remediation costs. UK Business in GBP terms grew by 2% in Q3 December 2016 over Q3 December 2015. India Business of the company grew by 5% in Q3 December 2016 over Q3 December 2015. However, India business during the quarter was de-grown by 18% in Q3 December 2016 over Q2 September 2016 mostly on account of demonetisation.

Wockhardt is a global pharmaceutical and biotech company with presence in USA, UK, Ireland, Mexico, Russia and many other countries.

Powered by Capital Market - Live News

Outcome of board meeting of Infibeam Incorporation
Jan 25,2017

Infibeam Incorporation announced that the Board of Directors of the Company at its meeting held on 24 January 2017 has passed the following resolutions subject to approval of shareholders -

To issue convertible warrants (one warrant fully convertible into one equity share) for an aggregate amount not exceeding Rs 60 crore on preferential basis at conversion price of Rs 1375 per equity share.

To obtain approval of members to increase limit for inter corporate loans/ investment/ guarantees; to create charge / mortgage on Companys assets ; and to increase borrowing limits from existing limit of Rs 1000 crore to Rs 3000 crore.

To convene EGM on 22 February 2017.

Powered by Capital Market - Live News

Biocon appoints company secretary and compliance officer
Jan 25,2017

Biocon announced that based on the recommendation by the Nomination and Remuneration Committee, Rajiv Balakrishnan was appointed as the Company Secretary and Compliance Officer of the Company by the Board of Directors at their meeting held 24 January 2017.

Powered by Capital Market - Live News

Biocon secures three year contract from Ministry of Health, Malaysia
Jan 25,2017

Biocon announced that Ministry of Health, Malaysia, has awarded a three year contract, to its subsidiary, Biocon SDN., Malaysia, for supplying recombinant human insulin (rh-insulin) formulations manufactured at its large scale biopharmaceutical facility in Johor, Malaysia.

Biocons rh-insulin is Malaysias first locally manufactured biosimilar biologic product approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia, for commercial sales in the country. This marks the commercialisation milestone of Biocons first overseas facility in Malaysia.

Biocon SDN. BHD. has been awarded a MYR 300 million (Rs 450 crore) contract to be serviced over a three year period for supplying rh-insulin cartridges and re-usable insulin pens under the Malaysian governments Off-Take Agreement (OTA) initiative, which seeks to encourage local manufacturing of new pharmaceutical products thus lowering the countrys reliance on imports and also enhancing the exports potential. The contract is extendable for additional two years subject to approval by the Government of Malaysia.

Powered by Capital Market - Live News

Bharti Airtel declines after poor Q3 results
Jan 25,2017

The result was announced after market hours yesterday, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 91.44 points or 0.33% at 27,467.02.

On the BSE, 72,000 shares were traded on the counter so far as against the average daily volumes of 1.40 lakh shares in the past one quarter. The stock had hit a high of Rs 312.95 and a low of Rs 304.10 so far during the day.

The stock had hit a 52-week high of Rs 384.90 on 28 April 2016 and a 52-week low of Rs 282.30 on 29 January 2016. The stock had outperformed the market over the past one month till 24 January 2017, advancing 7.06% compared with the Sensexs 5.13% rise. The scrip had also outperformed the market over the past one quarter, gaining 3.21% as against the Sensexs 2.85% fall.

The large-cap company has equity capital of Rs 1998.70 crore. Face value per share is Rs 5.

Bharti Airtels consolidated total revenue on an underlying basis adjusted for Africa divested operating units, tower assets sale and merger of Bangladesh operations declined 3% to Rs 23336 crore in Q3 December 2016 over Q3 December 2015.

The companys consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) rose 1.1% to Rs 8570 crore in Q3 December 2016 over Q3 December 2015. EBITDA margin edged up by 1.5% year-on-year at 36.7% in Q3 December 2016, led by Africa margin expansion of 4.9% on an underlying basis.

Bharti Airtels MD and CEO for India & South Asia, Gopal Vittal said, the quarter has seen turbulence due to the continued predatory pricing by a new operator. The present termination costs at 14 paise which are well below cost has resulted in a tsunami of minutes terminating into Airtels network. This has led to an unprecedented year-on-year revenue decline for the industry, pressure on margins and a serious impact on the financial health of the sector.

Vittal added that at the same time revenue market share of Airtel has crossed a lifetime high of 33%.

Bharti Airtels board in its meeting held yesterday, 24 January 2017, approved issuance of non-convertible debentures (NCDs) on a private placement basis. The outstanding under these NCDs shall at all times be within the overall borrowing limits and be subject to a cap of Rs 10000 crore.

Bharti Airtel is a leading global telecommunications company with operations in 18 countries across Asia and Africa.

Powered by Capital Market - Live News

Bharti Airtel in spotlight after reporting Q3 results
Jan 25,2017

Bharti Airtels consolidated net profit fell 54.54% to Rs 503.70 crore on 2.85% decline in total income to Rs 23415.60 crore in Q3 December 2016 over Q3 December 2015. The result was announced after market hours yesterday, 24 January 2017.

Bharti Airtels board in its meeting held yesterday, 24 January 2017, approved issuance of non-convertible debentures (NCDs) on a private placement basis. The outstanding under these NCDs shall at all times be within the overall borrowing limits and be subject to a cap of Rs 10000 crore.

Idea Cellular announced that it intends to issue unsecured redeemable non-convertible debentures (NCDs) amounting to Rs 2000 crore on private placement basis. The tenure of NCDs is five years and carry a coupon rate of 8.04% per annum. The announcement was made after market hours yesterday, 24 January 2017.

Wipro announced that TK Kurien, Executive Vice Chairman and member of the board will retire on 31 January 2017. The announcement was made after market hours yesterday, 24 January 2017. The company is scheduled to announce Q3 December 2016 results today, 25 January 2017.

Among other prominent results, Kotak Mahindra Bank and Maruti Suzuki India are scheduled to announce December 2016 quarter results today, 25 January 2017.

Siemens announced that it has won an order worth around Rs 366 crore from Oil and Natural Gas Corporation (ONGC). The order includes supply of material for overhauling of 18 power turbines through zero hour overhaul and time continued overhaul. The announcement was made after market hours yesterday, 24 January 2017.

Wockhardt reported consolidated net loss of Rs 53.91 crore in Q3 December 2016 compared with net profit of Rs 72.04 crore in Q3 December 2015. Total income dropped 10.34% to Rs 1000.81 crore in Q3 December 2016 over Q3 December 2015. The announcement was made after market hours yesterday, 24 January 2017.

Indian Overseas Bank reported a net loss of Rs 554.44 crore in Q3 December 2016, compared to net loss of Rs 1425.06 crore in Q3 December 2015. Total income declined 13.12% to Rs 5599.50 crore in Q3 December 2016 over Q3 December 2015. The result was announced after market hours yesterday, 24 January 2017.

Powered by Capital Market - Live News